Enliven Therapeutics Inc. Common Stock ELVN · Stock Open Enliven Therapeutics Inc. Common Stock in new tab
Enliven Therapeutics Inc. Common Stock Analysis (ELVN)
Is Enliven Therapeutics Inc. Common Stock a good investment? Enliven Therapeutics Inc. Common Stock (ELVN) is currently trading at 48.87 USD. Market analysts have a consensus price target of 73.90 USD. This suggests a potential upside from current levels.
Earnings Schedule: Enliven Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -2.34.
Investor FAQ
Does Enliven Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Enliven Therapeutics Inc. Common Stock?
Enliven Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -1.65.
Company Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 24, 2023 | 1:4 |
Community Discussion